Centrovet
Date: Nov 2021
Client: Centrovet
Counterparty: Virbac
Industry: Healthcare
Amount: USD 47.4 million
Transaction:
Landmark Alantra acted as financial advisor on the sale of the remaining 34% of Centrovet to Virbac, the world’s sixth largest animal health global company, for a total consideration of USD 47.4 million (including earnout).
Established in 1979, Centrovet is Chile’s second largest producer of salmon vaccines and has developed a leading position in aquaculture and animal health generally.
Virbac is a leading animal health company present in more than 100 countries around the world and covering more than 50 species. The company is listed on the Euronext Paris stock exchange (Euronext:VIRP) and has a market capitalization of EUR 3.5 billion.
Nov 2021
Financial advisor to
on the sale of 34% of the shares to
With this transaction, Virbac completes the acquisition of 100% of the company since the initial purchase in 2012
Similar transactions
Nov 2021
Financial advisor to
on the sale of 34% of the shares to
With this transaction, Virbac completes the acquisition of 100% of the company since the initial purchase in 2012
Leer más
